גלוקופג' XR 750 מג ישראל - עברית - Ministry of Health

גלוקופג' xr 750 מג

merck serono ltd - metformin hydrochloride - טבליות בשחרור ממושך - metformin hydrochloride 750 mg - metformin

סיטאגמט אס. קיי 1000 מג 50  מג ישראל - עברית - Ministry of Health

סיטאגמט אס. קיי 1000 מג 50 מג

k.s.kim international (sk- pharma) ltd., israel - metformin hydrochloride; sitagliptin - טבליות מצופות פילם - metformin hydrochloride 1000 mg; sitagliptin 50 mg - metformin and sitagliptin

סיטאגמט אס. קיי 850 מג 50  מג ישראל - עברית - Ministry of Health

סיטאגמט אס. קיי 850 מג 50 מג

k.s.kim international (sk- pharma) ltd., israel - metformin hydrochloride; sitagliptin - טבליות מצופות פילם - metformin hydrochloride 850 mg; sitagliptin 50 mg - metformin and sitagliptin

סיטאפורמין טבע 50 מג1000 מג ישראל - עברית - Ministry of Health

סיטאפורמין טבע 50 מג1000 מג

teva israel ltd - metformin hydrochloride; sitagliptin as malate - טבליות מצופות פילם - metformin hydrochloride 1000 mg; sitagliptin as malate 50 mg - metformin and sitagliptin

סיטאפורמין טבע 50 מג500 מג ישראל - עברית - Ministry of Health

סיטאפורמין טבע 50 מג500 מג

teva israel ltd - metformin hydrochloride; sitagliptin as malate - טבליות מצופות פילם - metformin hydrochloride 500 mg; sitagliptin as malate 50 mg - metformin and sitagliptin

סיטאפורמין טבע 50 מג850 מג ישראל - עברית - Ministry of Health

סיטאפורמין טבע 50 מג850 מג

teva israel ltd - metformin hydrochloride; sitagliptin as malate - טבליות מצופות פילם - metformin hydrochloride 850 mg; sitagliptin as malate 50 mg - metformin and sitagliptin

יוקריאס 50/850 מ"ג ישראל - עברית - Ministry of Health

יוקריאס 50/850 מ"ג

novartis pharma services ag - metformin hydrochloride 850 mg; vildagliptin 50 mg - film coated tablets - metformin - eucreas is indicated in the treatment of type 2 diabetes mellitus:• eucreas is indicated in the treatment of type 2 diabetes patients who are unable to achieve sufficient glycemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.• eucreas is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulphonylurea.• eucreas is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.

נובוגרד 1 מ"ג/500 מ"ג ישראל - עברית - Ministry of Health

נובוגרד 1 מ"ג/500 מ"ג

novo nordisk ltd - metformin hydrochloride 500 mg; repaglinide 1 mg - tablets - metformin - novogard is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 mellitus who are already treated with a meglitinide and metformin hcl or who have inadequate glycemic control on a meglitinide alone or metformin hcl alone.

נובוגרד 2 מ"ג/500 מ"ג ישראל - עברית - Ministry of Health

נובוגרד 2 מ"ג/500 מ"ג

novo nordisk ltd - metformin hydrochloride 500 mg; repaglinide 2 mg - tablets - metformin - novogard is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 mellitus who are already treated with a meglitinide and metformin hcl or who have inadequate glycemic control on a meglitinide alone or metformin hcl alone.

יוקריאס 50/500 מ"ג ישראל - עברית - Ministry of Health

יוקריאס 50/500 מ"ג

novartis pharma services ag - metformin hydrochloride 500 mg; vildagliptin 50 mg - film coated tablets - metformin - eucreas is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.